ArticleJournal of animal science and biotechnology2025
Bacillus velezensis MZ09 alleviates DSS-induced colitis in piglets by remodeling the intestinal microbiota activating the SCFAs-GPR43-STAT3 pathway and suppressing NLRP3 inflammasome-mediated pyroptosis.
Article in Journal of animal science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Microbial-enzymatic co-fermentation of feather meal for bioactive peptide production and its multi-pathway synergistic regulation of intestinal health in broilers.Poultry science · 2026Article
- Artemisia argyi-enriched fermented soybean meal alleviates ETEC K88-induced intestinal injury in mice in association with gut microbiota remodeling and purine metabolic alterations.BMC veterinary research · 2026Article
- Unraveling Streptococcus Thermophilus NCU074001-Based Anti-Diarrheal Actions Via Integrated Immune-Gut Microbiota and Tryptophan Metabolic Pathway Identification.Probiotics and antimicrobial proteins · 2026Article
- Probiotic Lactobacillus johnsonii RS-7 Alleviates Intestinal Inflammation Via the TLR4/MyD88/NF-κB Signaling Pathway.Probiotics and antimicrobial proteins · 2026Article
- Emerging microbiome-mitochondria crosstalk in host defense and infectious diseases: mechanistic insights into NLRP3 inflammasome activation and mtDNA-mediated immunomodulation.Frontiers in cellular and infection microbiology · 2026Review
- Circadian clock-gut microbiota axis in pulmonary hypertension: linking gut-lung crosstalk, immune timing and vascular remodeling.Frontiers in physiology · 2026Review
- Alternate-day fasting ameliorates α-synuclein pathology and suppresses inflammation via the gut-brain axis in an MPTP-induced subacute mouse model of Parkinson's disease.NPJ biofilms and microbiomes · 2025Article
- Dietary supplementation with sodium isobutyrate enhances growth performance and colonic barrier function in weaned piglets via microbiota-metabolite-host interactions.Journal of animal science and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) is closely associated with intestinal microbiota dysbiosis and metabolic dysfunction. The aim of this study was to explore the protective effects and mechanisms of the probiotic Bacillus velezensis MZ09, which produces branched-chain short-chain fatty acids (BSCFAs), against the dextran sulfate sodium (DSS)-induced colitis in piglets.
resultsIn this study, a DSS-induced piglet colitis model was established to explore the impact of MZ09. Pretreatment with MZ09 significantly alleviated the symptoms of colitis in piglets. For example, the disease activity index (DAI) score decreased, the length of the colon was restored, and splenomegaly was alleviated. MZ09 enhanced intestinal barrier integrity by upregulating the expression of tight junction proteins such as Claudin-1, Occludin, and ZO-1. Using 16S rRNA analysis, we found that MZ09 could remodel the intestinal microbiota. MZ09 increased the abundance of beneficial bacteria such as Firmicutes and Lactobacillus while suppressing the growth of harmful bacteria such as Proteobacteria and Escherichia-Shigella. MZ09 also increased the levels of short-chain fatty acids (SCFAs) in the colon. The increased SCFA content activated G-protein-coupled receptor 43 (GPR43), which increased the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and promoted the production of the anti-inflammatory cytokine interleukin-10 (IL-10). Mechanistically, MZ09 mitigated mitochondrial damage via the STAT3/hypoxia-inducible factor 1α (HIF-1α) axis. This action inhibits nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome-mediated pyroptosis, thus reducing the release of the proinflammatory cytokines IL-1β and IL-18.
conclusionsB. velezensis MZ09 alleviates DSS-induced colitis in piglets through multiple pathways, including gut microbiota remodeling, SCFAs-GPR43-STAT3 axis activation, and NLRP3 inflammasome-mediated pyroptosis suppression. These findings provide a new theoretical basis for the development of targeted intervention strategies for IBD, suggesting that MZ09 represents a potentially promising therapeutic agent for IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.